NCT06572306 Pharmacist-led Continuous Glucose Monitoring
| NCT ID | NCT06572306 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of South Florida |
| Condition | Type 2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-09-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study. The goal of this prospective cohort study is to determine impact of pharmacist-led continuous glucose monitoring on glycemic control and health behavior change in people with type 2 diabetes. The main questions it aims to answer are: 1. to assess change in hemoglobin A1c in people with type 2 diabetes using continuous glucose monitoring under a pharmacist-led approach as compared to a pharmacist-led approach utilizing no continuous glucose monitoring (only self-monitoring blood glucose with a glucometer). 2. to assess change in continuous glucose monitoring-derived glycemic outcomes among the pharmacist-led continuous glucose monitoring cohort (intervention group) 3. to assess change in health behavior among the pharmacist-led continuous glucose monitoring cohort (intervention group)
Eligibility Criteria
Inclusion Criteria: * type 2 diabetes * hemoglobin A1c ≥ 8% * compatible smartphone with FreeStyle Libre 2 or Libre 3+ continuous glucose monitoring system * current use and access to a glucometer for self-monitoring of blood glucose Exclusion Criteria: * any continuous glucose monitor use within 6 months prior to study enrollment * pregnant and planning to become pregnant during study time frame * history of hypoglycemia requiring third party assistance * history of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 6 months prior to study enrollment * known allergy to medical grade adhesives * current use of systemic steroids for any medical condition * current use of dialysis
Contact & Investigator
Kevin Cowart, PharmD, MPH
PRINCIPAL INVESTIGATOR
University of South Florida
Frequently Asked Questions
Who can join the NCT06572306 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06572306 currently recruiting?
Yes, NCT06572306 is actively recruiting participants. Contact the research team at kcowart2@usf.edu for enrollment information.
Where is the NCT06572306 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT06572306 clinical trial?
NCT06572306 is sponsored by University of South Florida. The principal investigator is Kevin Cowart, PharmD, MPH at University of South Florida. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.